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Objectives: In routine clinical practice the selection of a particular anticoagulant 
for treatment of a specific patient may be based on a variety of different factors. The 
aim of this study was to explore if there were differences in the characteristics of 
patients with non-valvular atrial fibrillation (NVAF) who started on dabigatran etex-
ilate (DE) and who in the prior year had no oral anticoagulant treatment (initiators) 
versus those who had previously been treated with warfarin (switchers). MethOds: 
Medco claims data were used to characterize 7,055 NVAF patients from the US with 
a DE prescription between Feb 2011 and Apr 2012. The first prescription in this 
period defined the index date. The treatment-groups were stratified by initiators 
and switchers. Characteristics, comedications, and comorbidities in the 12-month-
period prior to index date were assessed. All illustrated differences were statistically 
significant (p < 0.05) (1). Results: Switchers (N = 2,585) had a mean age of 74.0 
(±9.6) years, whereas initiators (N= 1,903) were younger (mean 70.0 (±9.6) years). 
A higher proportion of switchers used comedications compared to initiators, e.g. 
beta blockers (66% vs. 59%), and gastrointestinal drugs (34% vs. 28%). Switchers 
were more likely to have congestive heart failure, hypertension, cerebrovascular 
disease, renal disease and bleeding related hospitalizations when compared to the 
initiators, and also had a higher mean CHA2DS2-VASc score (4.0 (±1.8) compared to 
initiators (3.4 (±1.9)). cOnclusiOns: This study shows differences between patients 
who are initiating DE as first anticoagulant treatment and those who are switched 
from warfarin to DE revealing that switchers might represent a distinct patient 
population. Identifying, stratifying or accounting for such differences are necessary 
in comparisons using real world data. (1) Schoof N et al., Characteristics of patients 
with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr 
Med Res Opin. 2013 Dec 27.
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Objectives: In 2011, various legislative measures were adopted in Slovakia regarding 
drug policy. The aim of the submitted work is to evaluate links between the introduc-
tion of regulations and the consumption of antihypertensive drugs (AH), expendi-
tures and patient co-payments. MethOds: We evaluated data on drugs consumption 
based on IMS Data. Patient co-payments data were taken from the National Health 
Information database. When evaluating the average amount of co-payments, we 
applied a weighted average, which takes into account the level of co-payment and 
consumption. Results: The consumption of AH (in DOT) increased continually in 
2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introduc-
ing new regulations. The impact of new regulations was expressed foremost in the 
consumption of RAS inhibitors, where the decrease in turnover after introduction of 
clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced 
by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 
to € 3.76). At the same time, there was an increase in average co-payments by 105% 
(from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed 
AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 
more for one pack of fixed AH than for a free combination. After the introduction of 
regulations, the consumption of fixed combinations grew at a slower pace than in 
the case of monocomponents. cOnclusiOns: The legislative changes in drug policy 
had a significant impact on the consumption of antihypertensive drugs and on the 
expense of hypertension treatment. It is necessary to monitor long-term and analyse 
the impacts of regulations on the prescription of AH and to evaluate factors that can 
influence the success of hypertension treatment.
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Objectives: Oral anticoagulants (OACs), used for stroke prevention in atrial fibril-
lation, include warfarin and the newer drugs (NOACs) dabigatran, rivaroxaban and 
apixaban. High direct drug costs of the NOACs to the health care payer prompt 
monitoring of real-world NOAC uptake patterns. This study aimed to identify factors 
associated with anticoagulation initiation with NOACs versus warfarin. MethOds: 
Analyses were performed using national pharmacy claims data from a means-tested 
state medical services scheme. First-time initiators of an oral anticoagulant between 
January 2009 and December 2013 with ≥ 1 year scheme eligibility and ≥ age 50 
were identified. Patients whose claims amounted to < 90 days of oral anticoagula-
tion were excluded. Patient characteristics, and number and type of concomitant 
medications at the time of first oral anticoagulant were recorded and considered 
as predictors of NOAC initiation using multivariate logistic models (odds ratios, OR 
and 95% CIs). Results: 34,944 new initiators of oral anticoagulants were included. 
In 2009, 7.6% of new initiators received a NOAC; this figure rose to 41.2% in 2013. The 
following were positively associated with NOAC initiation in multivariate analyses: 
female gender (OR: 1.14,95% CI 1.07-1.21), age < 80 (OR: 1.11, 95% CI 1.04-1.19) and 
concomitant receipt of NSAID drugs (OR: 4.04, 95% CI 3.72-4.38). Receipt of multiple 
concomitant medications was negatively associated with NOAC initiation; patients 
receiving 15+ drug classes had a 42% decreased odds of NOAC receipt (versus ≤ 5 
drug classes) (OR: 0.58, 95% CI 0.51-0.66). Specific concomitant drugs negatively 
Objectives: Pharmaceutical expenditure accounted for between 11% to 13% of total 
health expenditure in European countries including Sweden in 2010 whereas this 
was 20% in Japan for the same year. We expect that big changes in sales pattern will 
happen as a result of patent expiry. Other changes have been seen when prescrib-
ers get negative/positive information on drugs. In this article we study the impact 
of patent expiry and negative information relating to pharmaceutical policies on 
pharmaceutical sales patterns of selected drugs in Sweden and Japan. MethOds: 
we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin 
Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregres-
sive integrated moving average (ARIMA) modeling with intervention analysis was 
used to estimate the change of sales volume. Results: Losartan had a positive 
change (0.77650, p= 0.0068) in October 2010, Candesartan had a negative change 
(-0.50760, p= 0.0058) in July 2010. There were no significant differences in the sales 
volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p= 0.7995, 
-0.38547, p= 0.0880, and -1.21215, p= 0.001, respectively). In this study, we used a 
publication informed that Candesartan and Telmisartan had not reduced patients’ 
mortality by a journal July in 2009 as negative information. cOnclusiOns: We 
found that the sales pattern of selected drugs were changed by negative information 
and not by the expiry of their patents in Sweden. Whereas in Japan the negative 
situation for implementing generic substitution like the therapeutic substitution 
of Trandolapril and the possibility of switching from Candesartan to a combination 
drug was seen. Further assessment will be needed since factors associated with the 
changing use of drugs will be infinite.
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Objectives: From April 2013, the method of calculating the prescription rate 
of generic drugs in Japan was changed and protected brand name drugs were 
excluded from the denominator. In the case of Japan, which does not have a 
reference pricing system, it is thought that this will lead to a change in prescrip-
tions toward protected brand name drugs rather than drug substitution to generic 
drugs. The objective of this study is to clarify the trends in relation to the prescrip-
tion of generic drugs, through the use of administrative data on a nationwide 
level. MethOds: We used survey data from dispensing pharmacies from April 
2012 to March 2014. As a comparison, we used the prescription data of 1139 acute 
care hospitals in which incentive measures for drug substitution to generic drugs 
had not taken place during the same period. The medical products in question 
were drugs for diabetes and hypotensive drugs. For data analysis used SQL Server 
2008 R2 and R. Results: As the dispensing pharmacy receives additional compen-
sation based on the rate of generic drugs dispensed by that pharmacy in the most 
recent 3 months, the dispensing rate of generic drugs will have a direct impact 
on their business. The change in the method of calculating generic drugs has a 
major impact on the dispensing pharmacies, and in this study we have shown 
the possibility of dispensing pharmacies shifting more to protected brand name 
drugs. The dispensing rate of generic drugs by acute care medical facilities has 
always been low, and thus the impact of the change in calculation of the dispens-
ing ratio is correspondingly low. cOnclusiOns: The results of this study show 
that when encouraging drug substitution to generic drugs as a policy to reduce 
drug expenditure, it is necessary to consider measures in relation to the shift to 
protected brand name drugs.
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Objectives: The objectives of this research are to provide an overview of the recalls 
of cardiac implant medical devices in the last decade according to the different 
categories of cardiac implant medical devices and analyze the recall reasons. On the 
basis of this analysis, this research will provide recommendations on how to build 
a high quality implant registry. MethOds: A systematic search was performed 
focusing on regulatory bodies’ homepages from a range of middle and high-income 
countries with sufficient information on cardiac implant recalls and the related 
reasons. Data was extracted for the years 2004-2014 with the following criteria 
applied: cardiac implant medical device recalls and reasons for recall, i.e. harm 
or risk to patients excluding labeling or legal problems. Results: 11 countries 
have been included in the study: United States, Canada, Australia, New Zealand, 
PR China, China Hong Kong, UK, Germany, Ireland, Switzerland and Saudi Arabia. 
104 recall reports have been analyzed in total. The categories of cardiac implants 
include the following: Implantable Cardioverter Defibrillator (ICD) 40.4%; pacemaker 
14.4%; stent 14.4%; as well as Cardiac Resynchronization Therapy (CRT) 13.5%; 
leads 9.6% and replacement materials 7.7%. Referring to the recall reasons, 32.7% 
of the reports related to problems with the device battery; 30.7% of devices were 
recalled due to incorrect therapy delivery; 15.4% devices had software problems; 
15.4% devices had connection problems and 5.8% of devices did not deliver correct 
output data. cOnclusiOns: Due to the high-risk nature of cardiac implants medi-
cal devices and their high complication rates associated with considerable associ-
ated mortality, the traceability and transparency of safety hazards information are 
crucial. By analyzing the recall information including recall reasons and cardiac 
implants categories, important information is gained that can inform a high qual-
ity cardiac implant registry for monitoring the safety of cardiac implant patients.
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lor example suggests that a positive National level (NICE) recommendation does 
not necessarily translate into common local prescribing behavior. Local variation 
(the fifth hurdle of market access) should be considered by pharmaceutical com-
panies when developing market access strategy.
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Objectives: Atherosclerotic cardiovascular diseases (CVD) remain the major cause 
of premature death in Europe. CVD treatment and precribing behavior remains 
a major challenge for the doctors, payers and regulatory bodies. Key aim of our 
study was to collect and compare reliable and comparable data on drug utiliza-
tion for CVD therapy in Slovakia during 8 years (2005-2012). MethOds: We uti-
lized review of available costs data sources connected to ATC classification and to 
cardiovascular diseases (C01-C10). We also looked for Daily Defined Doses (DDD) 
measurement units. We adopted time frame and data was consequently used for 
analysis. Costs were used in EUR. Results: Total increase in EUR spent on cardio-
vascular drugs was more than 60 million EUR (2012 vs 2005). Key growth drivers 
from selected ATC groups were Vasoprotectives and Calcium channel blockers with 
78% and 88% growth respectively (2012 vs. 2005). Amount of drug costs allocated 
for cardiovascular disease escalated in 2011 with almost 197 million EUR, average 
price for package reached 5,38 EUR in same year and price per 1 DDD was 0,17 EUR 
per 1 DDD (2012) compare to 0,16 EUR (2005). Overall unit sales results from 2005 to 
2012 show slide growth tendency till 2010 with following slight declined. Growth 
in units for all ATC group under our scope reached the level of 4,3% (2012 vs 2005). 
Standardized death rate for CVD decresed from 637,3 in 2005 to 510,4 in 2012 (per 
100.000). cOnclusiOns: Increase spending for CVD management translated also 
into decrease death rate (2012 vs 2005). It is important for regulatory bodies and 
payers to continue in taking adequate measures that will ensure rational pharmaco-
therapy alongside with improving prescribing behavior. Combining different meas-
ures, such as electronic prescription monitoring and promoting available guidelines 
for CVD management, could be an effective way.
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Objectives: According to National Cholesterol Education Program Adult Treatment 
Panel IV, lipid-lowing agent is required if in patient with atherosclerotic risks. The 
annual cost of statins consumption was the first five human medications in Taiwan. 
Therefore, disallowed/deduction of reimbursement from Administration of National 
Health Insurance (NHI) was relatively higher than other drugs. An “Automatic 
Laboratory data Checking System” was established in order to enhance rational 
use of statins and to reduce deduction rate of statins reimbursement. This study 
aims to analyze the economic outcomes after implemented the system. MethOds: 
The major cause of deduction was the lipid profile fragmented in the medical record. 
To ensure rational use of statins based on NHI regulation, an “Automatic Laboratory 
data Checking System” in computerized physician order entry (CPOE) system was 
implemented in a teaching hospital on February 2013. When processing a statin 
prescription through CPOE system, the prescriber should choose the lipid profile 
linked with laboratory system in our hospital, or filled in lipid profile performed at 
outside source. The prescription would be blocked if the inspection date and labora-
tory data were not adherence to the NHI regulation. Results: After system imple-
mentation, the deduction of statins reimbursement was significantly decreased. 
There were three indicators substantially improved in year 2013 than 2012: The 
average quarterly deduction was 2.16 million NTD reduced, the average quarterly 
deduction rate was 14% reduced (18.18% versus 3.95%), and the disallowed reim-
bursement account for 57.11% medication fee decreased to 7.17%. cOnclusiOns: 
The present study demonstrated that “Automatic Laboratory data Checking System” 
lessen the economic burden of statins reimbursement based on NHI regulations. 
The system was associated with rational use of statins and reducing disallowed 
reimbursement as well.
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Objectives: This real-world study evaluated the baseline characteristics of patients 
with non-valvular atrial fibrillation (NVAF) who had switched from warfarin to novel 
oral anticoagulants (NOACs). MethOds: Retrospective cohort study was conducted 
using the MarketScan® plus Earlyview data from 10/1/2009 to 12/31/2013. Adult 
NVAF patients (ICD-9 code 427.31 or 472.32) with one year of baseline period and 
a history of continuous warfarin use in the baseline period for at least 3 months 
immediately before the index date (defined as the first NOAC claim) were included. 
Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral 
stenosis, VTE, cardiac surgery, and endocarditis during the baseline period were 
excluded. Categorical variables were reported as percentages and frequencies, 
and continuous variables as means±SD. Categorical variables were compared 
using Pearson’s chi-squared test while continuous variables were compared using 
wilcoxon signed-rank test. Results: Among 11,743 eligible patients, 427 (3.64%) 
switched to apixaban, 8,989 (76.55%) to dabigatran and 2,327 (19.81%) to rivaroxaban. 
associated with NOAC use included rate/rhythm control treatments (OR: 0.78, 95% 
CI 0.73-0.83) and SSRI/SNRI antidepressants (OR: 0.87, 95% CI 0.79-0.96). Regional 
variation in initiation of NOACs versus warfarin was also observed. cOnclusiOns: 
Multiple comorbidities may be associated with lower likelihood of NOAC initiation, 
as recently observed in other jurisdictions. Such uptake patterns have implications 
for real-world cost-effectiveness and outcomes studies.
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Objectives: The objective of generic drugs policies can be defined as reduction in 
health care expenditure without compromising health outcomes. This definition 
is based on the disinvestment aspect of drug policies. However, the objective of 
generic drug policies can be also defined from an investment perspective, espe-
cially in those countries with volume limits for the use of original patented drugs 
due to economic constraints: increase in population health gain by improved 
patient access without need for additional health expenditure. Our objective was 
to compare benefits of generic drugs policies in Germany vs Hungary. MethOds: 
We reviewed the grey literature and IMS database to identify pharmaceutical prod-
ucts with (1) patent expiry in recent years, (2) major therapeutic advancement to 
previous standard therapies, (3) no direct therapeutic alternative at patent expiry, 
(4) pharmacy distribution and consequently reliable IMS sales records in differ-
ent countries. Then we compared aggregated annual volume sales in DOT and 
ex-factory sales for the selected pharmaceuticals in +/- 3 years before and after 
first generic entry. Results: In this analysis we present the case of clopidogrel. In 
Germany the volume sales of clopidogrel products increased by 1.7% with 3 years 
after first generic entry, in Hungary the increase was 120.5%. The ex-factory sales 
were reduced after patent expiry in both countries, by 30.1% in Germany and by 
59.5% in Hungary. cOnclusiOns: In Germany off-patent clopidogrel generated 
significant savings without volume increase. In Hungary generic products signifi-
cantly improved the accessibility of patients to clopidogrel therapy, in addition 
to reducing pharmaceutical expenditure. Incremental health gain of off-patent 
medicines should not be underestimated in those countries, where accessibility 
of patients to patented medicines in restricted.
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Objectives: From the total health care costs in Slovak Republic the costs of medi-
cines for treatment of cardiovascular diseases represent about 25%. In the world 
the proportion is at 8-10%. Accurate data on morbidity from cardiovascular disease 
in Slovak Republic is not available. National Health Information Center is process-
ing the data on prevalence and incidence of circulatory system diseases, but this 
includes only those patients who are followed in cardiology in SR. Reportedly, 
the prevalence of cardiovascular diseases in SR is about 250 000 patients (50.8/ 
1000 inhabitants). MethOds: The utilization of medicines in period from 2008 
to 2013 for treatment of cardiovascular diseases was analysed quantitatively by 
inderect descriptiv method of evaluating supply of medicines in quantitative units 
(number of packages), in the number of DDD and in financial indicators reflect-
ing the full value of consumed package. Data were gained from National Health 
Center and State Institute of Drug Control. Results: The decline of consumption 
expressed in number of packages was observed in the group of cardiac therapy 
and by peripheral vasodilatators. The groups of beta blocking agents, agents acting 
on the renin-angiotensin system and lipid modifying agents showed increase in 
consumption. In DDD units the consumption deacreased most significantly in the 
group of peripheral vasodilatators. Rise in DDD units was observed in the group 
of beta blocking agents, antihypertesives, beta blocking agents, agents acting on 
the renin-angiotensin system and lipid modifying agents. Atorvastatin was active 
agent with highest consumption in DDD. The highest average price per package was 
calculated by lipid modifying agents. After access of generic drugs to the market 
in 2008 the consumption in financial units declined while consumption in DDD 
grew in followed period. cOnclusiOns: By using the same amount of health care 
expenditures there is the possibility to provide treatment to more patients with 
cardiovascular disease.
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Objectives: To understand the level of local variation in community-level 
prescribing of ticagrelor in England, after national-level recommendation from 
NICE. MethOds: Monthly GP-Practice-level prescribing data was collected for 
antiplatelet drugs (Chapter 2.9 of British National Formulary [BNF]) in England, 
between August 2011 and February 2013. Data was obtained from the Health 
and Social Care Information Centre (HSCIC) and analyzed in Statistical Analysis 
Software (SAS). The percentage of total antiplatelet spend (net ingredient cost) 
attributed to ticagrelor was calculated for each GP Practice and Clinical com-
missioning Group (CCG) cluster. Results: Despite national-level NICE guid-
ance (December 2011) recommending the use of ticagrelor for Acute Coronary 
Syndrome, uptake of ticagrelor at CCG level varied greatly between August 2011 
and February 2013. The proportion of total antiplatelet spend on ticagrelor in 
February 2013 ranged from 0% to 34∙91%, between CCGs. The highest relative use of 
ticagrelor was clustered around the Yorkshire region. cOnclusiOns: The ticagre-
